The management of geographic atrophy (GA) secondary to age-related macular degeneration has entered a new era with the availability of therapies that can slow lesion progression. Understanding the mechanisms of action, clinical evidence, and appropriate use of these agents is increasingly important in retinal practice. Here is a quick question on the management of geographic atrophy! (Scroll down to answer the question) ##Reference## Heier JS, Boyer D, Loewenstein A, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): phase 3, multicentre, randomised, double-masked, sham-controlled trials.
Lancet. 2023;402(10414):1434-1448. doi:10.1016/S0140-6736(23)01517-6.## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no explicit or…
